Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432185 · ClinicalTrials.gov registry record · Phase 2
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
A Phase 2 study of Superficial Basal Cell Carcinoma, sponsored by Peplin.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
- 9
- Study locations
NCT00432185: Completed Phase 2 study of Superficial Basal Cell Carcinoma, sponsored by Peplin.
NCT00432185 is a Phase 2 study of Superficial Basal Cell Carcinoma that has completed, run by Peplin. The registered enrollment target is 117 participants, above the 93-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (26% higher). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00432185, a Phase 2 study of Superficial Basal Cell Carcinoma, has completed, sponsored by Peplin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine maximum tolerated dose level (MTD) of PEP005 Topical Gel for the treatment of superficial basal cell carcinoma on the trunk
Conditions Studied
Interventions
- DRUG PEP005
Study Locations (9)
California
- Dermatology Specialists Inc. - Oceanside
- Skin Surgery Medical Group Inc. - San Diego
Florida
- Advanced Dermatology and Cosmetic Surgery - Clermont
- Park Avenue Dermatology - Orange Park
Arizona
- Alta Dermatology - Mesa
Colorado
- Colorado Medical Research Center - Denver
Minnesota
- Minnesota Clinical Studies Center - Fridley
New York
- Dermatology Associates of Rochester - Rochester
Tennessee
- Rivergate Dermatology and Skin Care Center - Goodlettsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00432185 record still lists
NCT00432185 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 5 other Superficial Basal Cell Carcinoma trials with a reported enrollment target (26% higher).
The record links to 1 condition, with Superficial Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which PEP005 is the first listed.
NCT00432185 lists 9 locations in 7 states (California, Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT00432185 about?
NCT00432185 is a clinical study titled "To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC". The purpose of this study is to determine maximum tolerated dose level (MTD) of PEP005 Topical Gel for the treatment of superficial basal cell carcinoma on the trunk
What is the current status of trial NCT00432185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2007-02. Estimated completion is 2010-03.
What conditions does trial NCT00432185 study?
This clinical trial studies the following conditions: Superficial Basal Cell Carcinoma.
What interventions are being tested in trial NCT00432185?
The interventions under investigation include: PEP005 (DRUG).
Who is sponsoring clinical trial NCT00432185?
This trial is sponsored by Peplin, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00432185 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Superficial Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
RECRUITING · Phase 2
-
Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
RECRUITING · Phase 1
-
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
RECRUITING · NA
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia